The U.S. Market For Obesity Treatment & Weight Management

2. Introduction

2.1 Scope and Objectives of Report
2.2 Methodology
2.3 Importance of Obesity and Weight Loss Study

3. Overview of Obesity and Weight Loss Management

3.1 Description and Diagnosis
3.2 Etiology and Pathophysiology
3.3 Causes
3.4 Assessment
3.5 Costs
3.6 Health Risks
3.7 Weight Management
3.8 Prevalence, Incidence, Mortality

4. Trends in Obesity Treatment and Management

4.1 Education
4.2 Federal and Clinical Guidelines
4.3 Direct-to-Consumer Advertising
4.4 Regulatory Issues
4.5 Reimbursement Issues
4.6 Weight Loss Programs
4.7 Alternative Treatments
4.8 Discoveries
4.8.1 Obesity Virus
4.8.2 Fat Formation Molecular Switch
4.8.3 Cinnamon Extract
4.9 Diet Drug Shortage
4.10 Food Trends

5. Prescription Anti-obesity and Weight Loss Pharmaceutical Market

5.1 Treatment Option Overview
5.1.1 Potential Benefits of Medication Treatment
5.1.2 Potential Drawbacks of Medication Treatment
5.2 Appetite Suppressants
5.2.1 Adrenergic Agents
5.2.2 Serotonergic Agents
5.3 Lipase Inhibitors
5.4 Market Size and Growth
5.5 Competitive Analysis

6. Over-the-Counter Anti-obesity and Weight Loss Pharmaceutical Market

6.1 Appetite Suppressants
6.1.1 Noradrenergic Agents
6.1.2 Caffeine-Based Agents
6.1.3 Benzocaine-Based Agents
6.2 Fat Substitutes
6.3 Market Size and Growth
6.4 Competitive Analysis

7. Surgical Interventions

7.1 Description of Procedures
7.2 Procedure Volumes
7.3 Market Size and Growth
7.4 Market Analysis

8. Research and Development for Obesity and Weight Loss Management

8.1 Gene And Protein Discoveries
8.1.1 ACRP 30
8.1.2 ATP Binding Cassette-1
8.1.3 Agouti Related Protein
8.1.4 CAPN-10
8.1.5 CREB
8.1.6 DGAT
8.1.7 Fatty Acid Transport Protein 4
8.1.8 Follistatin
8.1.9 GATA
8.1.10 Genetically Engineered Antibodies
8.1.11 GNB3 825T
8.1.12 HMGIC
8.1.13 IRS-2
8.1.14 Mahogany Gene
8.1.15 Melanin-Concentrating Hormone
8.1.16 Melanin-Concentrating Hormone Receptor
8.1.17 Melanocortin-3 Receptor
8.1.18 Melanocortin-4 Receptor
8.1.19 Tubby Gene
8.1.20 Tyrosine Phosphatase
8.1.21 Uncoupling Protein Homologue
8.1.22 ZN-2-Glycoprotein
8.2 Pharmaceutical Research
8.2.1 Amylase Inhibitors
8.2.2 Aminosterol
8.2.3 â3-Receptor Agonists
8.2.4 Botanical
8.2.5 Bupropion
8.2.6 C75
8.2.7 CART Peptides
8.2.8 Cholecystokinin
8.2.9 Ciliary Neurotrophic Factor
8.2.10 Corticotropin-Releasing Factor
8.2.11 Desmethylsibutramine
8.2.12 Ecopipam
8.2.13 Galanin Agonist
8.2.14 Glucagon-Like Peptide I
8.2.15 H3 Histamine Antagonist
8.2.16 Human Growth Hormone Fragment
8.2.17 Human Steroidal Hormone
8.2.18 Intestinal Fat Absorber
8.2.19 Leptin
8.2.20 Leptin Promoters
8.2.21 Leptin Receptor
8.2.22 Lipase Inhibitors
8.2.23 Melanocortin
8.2.24 Melanin-Concentrating Hormone Receptor
8.2.25 Neuropeptide Y Inhibitors
8.2.26 Orlistat
8.2.27 Peroxisome Proliferation Activated Receptor-Gamma
8.2.28 RXR:PPARy BR> 8.2.29 R-Fluoxetine
8.2.30 Serotonin 2-C Receptor
8.2.31 Topiramate
8.3 Device Research

9. Total Market Size and Forecast

9.1 Market Size and Forecast

10. Company Profiles

10.1 Amgen, Inc.
10.2 Aventis Pharmaceuticals, Inc.
10.3 Celltech Group plc
10.4 Chattem, Inc.
10.5 Gate Pharmaceutical
10.6 Heritage Consumer Products, LLC
10.7 Knoll Pharmaceutical Co.
10.8 Novartis Pharmaceuticals Corp.
10.9 Pharmacia Corp.
10.10 The Procter & Gamble Company
10.11 Regeneron Pharmaceuticals, Inc.
10.12 Roche Laboratories, Inc.
10.13 Watson Pharmaceuticals, Inc.

11. Emerging Companies

11.1 Alizyme plc
11.2 Cyberonics, Inc.
11.3 Gliatech, Inc.
11.4 Ligand Pharmaceuticals, Inc.
11.5 Neurocrine Biosciences, Inc.
11.6 Neurogen Corp.
11.7 NeoTherapeutics, Inc.
11.8 Phytopharm Co.
11.9 Sepracor, Inc.
11.10 Trega Biosciences, Inc.

Appendix A: Selected Weight Loss Programs

Appendix B: Common Brand and Generic Products with Active Ingredient Phenylpropanolamine